Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Ceva Swine Offer >
Complementarities between swine autogenous vaccines produced by Ceva Biovac and Ceva swine offer.
Ceva continues to deliver double-digit growth >
Sales up 20% versus S1 2016, driven by organic growth and acquisitions
Ceva Phylaxia inaugurates state of the art vaccine plant to support “Innovation with Impact” growth plan >
7,8 billion forint (€ 25m) investment will significantly increase production at its Budapest Campus
Ceva announces important advances in the control of respiratory disease in poultry >
Ceva Vaccination Summit details new claims for IB Vaccines.
Ceva shines light on the future with focus on innovation during VIV Asia 2017 >
Ceva’s teams brought innovation to the fore during VIV Asia 2017
World Veterinary Association and Ceva Santé Animale announce the creation of the Global Animal Welfare Awards 2017 >
As global understanding and concern for animal welfare continues to change, so must the veterinary community evolve to embrace these changes and reflect societal expectations.
Ceva honours rare livestock breeds during the French National Prize for Animal Agro biodiversity Awards ceremony >
The Fondation du Patrimoine and Ceva Santé Animale awarded the “Fondation du Patrimoine National Animal Agro-Biodiversity Prize” to 3 associations committed to preserving regional livestock breed, during the Paris International Agricultural Show.
Ceva reinforces its position in China and swine through new joint-venture with EBVAC >
In the presence of the Chinese Prime Minister, Li Keqiang and French Prime Minister, Bernard Cazeneuve, Ceva Santé Animale (Ceva) and EBVAC today signed a joint-venture agreement to create a new business, Ceva EBVAC, focused on the swine sector.
Ceva Santé Animale confirms its circle of virtuous growth in 2016 >
2016 was a year of sustained organic growth and major acquisitions. Consolidated sales reached €912m as the Ceva Group continued to achieve double-digit growth, cementing its position as the 6th. largest animal health company.
Ceva stresses the need for continued innovation to ensure effective disease control at IPPE 2017 >
Vectormune® ND, vaccine for Newcastle Disease (ND) Cevac IBird®, for Infectious Bronchitis (IB) prevention will continue to lead offerings for effective and easily administered disease control.